Rakuten Medical, Inc. is a global clinical stage biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its IlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. The company’s first drug developed on the Illuminox platform, ASP-1929, has received approval from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives. The company has 6 locations in 5 countries, including the United States, where it is headquartered, Japan, the Netherlands, Taiwan, and Switzerland. For more information, visit www.rakuten-med.com.
Total Funding: $618,600,000
Funding Stage: Series D
Business Stage: Scaling Up
Market: B2B
Company Size: 101 to 250
Founded: 2013
Oct 2021
- Data from Phase 1/2a was Published in Head and Neck
Oct 2021
- Rakuten Medical and Karkinos Healthcare Announce Strategic Partnership
Aug 2021
- Rakuten Medical Announced Two New Members to Board of Directors
Jul 2021
- Rakuten Medical Raised $166M Series D Financing led by General Catalyst
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Rakuten Medical
